Acasti Pharma  logo
Acasti Pharma ACST
report update icon

Quarterly report 2027-Q2
added 11-12-2026

Acasti Pharma Gross Profit | ACST

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Acasti Pharma

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - 120 K - - - - -32.3 K 28.4 K 188 K 310 K 122 K 29 K

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
310 K -32.3 K 109 K

Quarterly Gross Profit Acasti Pharma

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - - - - - - - - - - - - - - 120 K - - - 45 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
120 K 45 K 82.5 K

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
Sesen Bio Sesen Bio
SESN
990 K - 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
2.04 M - - $ 26.8 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
21 M - 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
33.4 M - 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
4.39 M - - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
1.82 K - -5.38 % $ 6.06 M usaUSA
Merus N.V. Merus N.V.
MRUS
-17.7 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
5.04 M - - $ 2.36 B usaUSA
Galapagos NV Galapagos NV
GLPG
1.08 B - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
1.94 M - -4.36 % $ 27 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
18.2 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
1.5 M - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
936 K - - $ 35.3 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
174 M - 0.52 % $ 821 M danmarkDanmark
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
53 K - -23.04 % $ 26.6 M usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
40 M - - $ 69.7 B britainBritain
Guardion Health Sciences Guardion Health Sciences
GHSI
5.39 M - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
23.4 M - - $ 109 M usaUSA
ImmunoGen ImmunoGen
IMGN
-32.3 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
113 K - -8.77 % $ 12.4 M israelIsrael
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
-119 K - -2.99 % $ 2.47 M usaUSA